1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-2247, NCT00442533
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-301, NCT00704730
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0189, 07-C-0189, NCT00514046
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI
Protocol IDs: 090089, 09-C-0089, NCT00923247
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-06054, 7609, IRB 2006C0050, NCI-7609, NCT00390325
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CO07203, NIH R21CA117117-01A2, NCT00501540
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UPCC-03305, UPCC#03305, UPCC-802861, NCT00601783
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0195, CO 07312, NCT00582712
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC057H, MC057H, 7627, NCT00625846
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787/ZK222584, NCT00627198
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0710, NCT00781911
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-201, NCT00784303
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CAP/TEM for Neuroendocrine CA, AAAB3348, NCT00869050
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-049, NCT00936858
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SU-03272009-2039, END0008, NCT00947167
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-2009-0173, CO 08322, NCT01013597
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: N05-10564, NCT00314925
|
|
20.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0047, NCI-P6880, NCT00436735
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0414, MC0414, NCT00655655
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-087, NCT00804336
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000449681, CASE-CCF-7509, CASE-CCF-1062, NCT00311558
|
|
24.
|
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 100
Sponsor: NCI
Protocol IDs: JHOC-J0628, NCT00416949
|
